Cara Therapeutics, Inc. (CARA)
Largest Insider Buys in Sector
CARA Stock Price History Chart
CARA Stock Performance
About Cara Therapeutics, Inc.
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
Insider Activity of Cara Therapeutics, Inc.
Over the last 12 months, insiders at Cara Therapeutics, Inc. have bought $0 and sold $58,024 worth of Cara Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Cara Therapeutics, Inc. have bought $0 and sold $2.71M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,000,000 shares for transaction amount of $18.19M was made by RHO Ventures VI LP (10 percent owner) on 2017‑03‑31.
List of Insider Buy and Sell Transactions, Cara Therapeutics, Inc.
| 2024-05-02 | Sale | Posner Christopher | PRESIDENT AND CEO | 3,936 0.007% | $0.75 | $2,952 | -11.96% | |
| 2024-04-05 | Sale | Terrillion Scott | SEC'Y; CHIEF COMPLIANCE & G.C. | 2,753 0.0048% | $0.83 | $2,285 | -18.81% | |
| 2024-04-05 | Sale | Goncalves Joana | CHIEF MEDICAL OFFICER | 2,753 0.0048% | $0.83 | $2,285 | -18.81% | |
| 2024-02-29 | Sale | Posner Christopher | PRESIDENT AND CEO | 5,834 0.0115% | $0.89 | $5,192 | -11.06% | |
| 2024-02-29 | Sale | Terrillion Scott | SEC'Y; CHIEF COMPLIANCE & G.C. | 3,293 0.0065% | $0.89 | $2,931 | -11.06% | |
| 2024-02-29 | Sale | Goncalves Joana | CHIEF MEDICAL OFFICER | 3,293 0.0065% | $0.89 | $2,931 | -11.06% | |
| 2024-02-08 | Sale | Posner Christopher | PRESIDENT AND CEO | 35,575 0.0607% | $0.53 | $18,855 | +44.78% | |
| 2024-02-01 | Sale | Posner Christopher | PRESIDENT AND CEO | 4,981 0.0088% | $0.55 | $2,740 | +33.69% | |
| 2023-11-02 | Sale | Posner Christopher | President and CEO | 3,796 0.0072% | $1.22 | $4,631 | -36.88% | |
| 2023-08-03 | Sale | Posner Christopher | President and CEO | 4,307 0.0077% | $3.07 | $13,222 | -72.21% | |
| 2023-06-23 | Sale | Menzaghi Frederique Ph.D. | Chief Scientific Off,SVP-R&D | 2,993 0.0056% | $3.51 | $10,505 | -72.46% | |
| 2023-06-23 | Sale | Terrillion Scott | Sec'y; Chief Compliance & G.C. | 2,483 0.0046% | $3.51 | $8,715 | -72.46% | |
| 2023-06-23 | Sale | Goncalves Joana | Chief Medical Officer | 2,723 0.0051% | $3.51 | $9,558 | -72.46% | |
| 2023-05-05 | Sale | Posner Christopher | President and CEO | 3,869 0.0072% | $4.40 | $17,024 | -71.98% | |
| 2023-04-04 | Sale | Menzaghi Frederique Ph.D. | Chief Scientific Off,SVP-R&D | 2,733 0.0053% | $4.91 | $13,419 | -66.14% | |
| 2023-04-04 | Sale | Terrillion Scott | Sec'y; Chief Compliance & G.C. | 2,481 0.0048% | $4.91 | $12,182 | -66.14% | |
| 2023-04-04 | Sale | Goncalves Joana | Chief Medical Officer | 2,481 0.0048% | $4.91 | $12,182 | -66.14% | |
| 2023-03-03 | Sale | Posner Christopher | President and CEO | 5,987 0.0105% | $9.71 | $58,134 | -76.65% | |
| 2023-03-03 | Sale | Menzaghi Frederique Ph.D. | Chief Scientific Off,SVP-R&D | 6,802 0.012% | $9.71 | $66,047 | -76.65% | |
| 2023-03-03 | Sale | Terrillion Scott | Sec'y; Chief Compliance & G.C. | 6,256 0.011% | $9.71 | $60,746 | -76.65% |
Insider Historical Profitability
| Posner Christopher | PRESIDENT AND CEO | 176585 0.3421% | $0.29 | 0 | 13 | |
| Terrillion Scott | Sec'y; Chief Compliance & G.C. | 88247 0.1626% | $0.29 | 0 | 18 | |
| Goncalves Joana | Chief Medical Officer | 53365 0.0985% | $0.29 | 0 | 27 | |
| RHO Ventures VI LP | 10 percent owner | 3568057 6.5492% | $0.29 | 4 | 0 | +18.29% |
| ALTA BIOPHARMA PARTNERS III LP | 10 percent owner | 1753447 3.2185% | $0.29 | 1 | 0 | +7.74% |
| Slagel Dean | director | 1064338 1.9536% | $0.29 | 0 | 6 | |
| CHALMERS DEREK T | President & CEO | 991405 1.8197% | $0.29 | 0 | 42 | |
| Lewis Michael E | Chief Scientific Advisor | 314988 0.5782% | $0.29 | 0 | 7 | |
| Menzaghi Frederique Ph.D. | Chief Scientific Off,SVP-R&D | 153747 0.2822% | $0.29 | 0 | 47 | |
| Reilly Thomas Charles | Chief Financial Officer | 37811 0.0694% | $0.29 | 0 | 2 | |
| Schoell Josef | Chief Financial Officer | 28000 0.0514% | $0.29 | 1 | 1 | <0.0001% |
| BAINS HARRISON M JR | 25076 0.046% | $0.29 | 0 | 1 | ||
| VOGELBAUM MARTIN | director | 20160 0.037% | $0.29 | 3 | 2 | +32.73% |
| Mohindru Mani | CFO & Chief Strategy Officer | 17441 0.032% | $0.29 | 0 | 7 | |
| Ives Jeffrey L. | 15476 0.0284% | $0.29 | 0 | 16 | ||
| Maynard Ryan D | CHIEF FINANCIAL OFFICER | 8012 0.0147% | $0.29 | 0 | 1 | |
| Stauffer Joseph William | Chief Medical Officer | 2000 0.0037% | $0.29 | 1 | 1 | <0.0001% |
Institutional Investor Ownership
| BlackRock | $3.11M | 6.26 | 3.42M | -3.74% | -$120,934.44 | <0.0001 | |
| The Vanguard Group | $2.26M | 4.54 | 2.48M | -5.69% | -$136,326.14 | <0.0001 | |
| Disciplined Growth Investors Inc Mn | $1.65M | 3.32 | 1.82M | +0.16% | +$2,691.78 | 0.03 | |
| Chescapmanager Llc | $1.55M | 3.11 | 1.7M | -2.85% | -$45,501.82 | 0.26 | |
| Farallon Capital | $1.42M | 2.85 | 1.56M | 0% | +$0 | 0.01 | |
| Renaissance Technologies | $1.21M | 2.44 | 1.33M | +91.17% | +$578,469.91 | <0.01 | |
| Geode Capital Management | $929,765.00 | 1.87 | 1.02M | +1.25% | +$11,503.76 | <0.0001 | |
| State Street | $912,688.00 | 1.83 | 1M | -1.76% | -$16,310.84 | <0.0001 | |
| Stifel | $674,650.00 | 1.36 | 741,374 | +136.82% | +$389,767.36 | <0.01 | |
| Millennium Management LLC | $602,269.00 | 1.21 | 661,834 | +41.66% | +$177,128.79 | <0.0001 | |
| Two Sigma Advisers LP | $600,509.00 | 1.21 | 659,900 | +28.34% | +$132,587.00 | <0.01 | |
| Bank of America | $578,969.00 | 1.16 | 636,230 | -1.33% | -$7,814.17 | <0.0001 | |
| Acuitas Investments, LLC | $466,114.00 | 0.94 | 512,213 | New | +$466,114.00 | 0.25 | |
| Northern Trust | $355,634.00 | 0.72 | 390,807 | -0.26% | -$914.55 | <0.0001 | |
| Verition Fund Management Llc | $355,448.00 | 0.71 | 390,602 | -28.98% | -$145,078.64 | <0.01 | |
| Acadian Asset Management | $303,000.00 | 0.61 | 334,231 | -7.28% | -$23,789.91 | <0.01 | |
| Charles Schwab | $299,200.00 | 0.6 | 328,791 | +22.4% | +$54,757.46 | <0.0001 | |
| Two Sigma | $252,960.00 | 0.51 | 277,978 | -9.53% | -$26,656.63 | <0.0001 | |
| Voya Investment Management LLC | $183,703.00 | 0.37 | 201,871 | +39.33% | +$51,851.00 | <0.0001 | |
| Assenagon Asset Management S.A. | $157,731.00 | 0.32 | 173,331 | +3.27% | +$4,998.62 | <0.0001 | |
| Fidelity Investments | $147,543.00 | 0.3 | 162,135 | +3.06% | +$4,387.11 | <0.0001 | |
| LINSCO PRIVATE LEDGER CORP | $137,196.00 | 0.28 | 150,764 | -3.06% | -$4,332.53 | <0.0001 | |
| BNY Mellon | $130,579.00 | 0.26 | 143,494 | -10.76% | -$15,745.67 | <0.0001 | |
| D. E. Shaw & Co. | $128,447.00 | 0.26 | 141,150 | -3.88% | -$5,190.66 | <0.0001 | |
| Nuveen | $103,676.00 | 0.21 | 113,930 | 0% | +$0 | <0.0001 | |
| Morgan Stanley | $96,335.00 | 0.19 | 105,863 | -63.89% | -$170,428.77 | <0.0001 | |
| Tealwood Asset Management | $85,757.00 | 0.17 | 94,238 | New | +$85,757.00 | 0.02 | |
| Tudor Investment Corp Et Al | $84,736.00 | 0.17 | 93,116 | 0% | +$0 | <0.01 | |
| AllianceBernstein | $79,461.00 | 0.16 | 87,320 | 0% | +$0 | <0.0001 | |
| RhumbLine Advisers | $69,982.00 | 0.14 | 76,918 | +4.28% | +$2,870.50 | <0.0001 | |
| Penserra Capital Management Llc | $59,000.00 | 0.12 | 65,538 | -19.63% | -$14,407.46 | <0.01 | |
| Susquehanna International Group | $56,252.00 | 0.11 | 61,815 | +35.33% | +$14,684.76 | <0.0001 | |
| National Asset Management Inc | $93,489.00 | 0.1 | 55,648 | -9.75% | -$10,096.84 | <0.01 | |
| Citigroup | $48,261.00 | 0.1 | 53,034 | +4.81% | +$2,215.85 | <0.0001 | |
| UBS | $46,803.00 | 0.09 | 51,432 | +41.11% | +$13,634.50 | <0.0001 | |
| Goldman Sachs | $46,995.00 | 0.09 | 51,643 | -75.39% | -$143,987.99 | <0.0001 | |
| Gsa Capital Partners Llp | $41,000.00 | 0.08 | 45,268 | -79.89% | -$162,933.07 | <0.01 | |
| Group One Trading | $36,377.00 | 0.07 | 39,975 | +0.13% | +$45.50 | <0.01 | |
| Xtx Topco Ltd | $32,975.00 | 0.07 | 36,236 | +33.1% | +$8,200.98 | <0.01 | |
| Envestnet Asset Management Inc | $32,570.00 | 0.07 | 35,791 | New | +$32,570.00 | <0.0001 | |
| JPMorgan Chase | $30,976.00 | 0.06 | 34,040 | +9.25% | +$2,623.50 | <0.0001 | |
| Barclays | $29,000.00 | 0.06 | 32,422 | -49.35% | -$28,255.81 | <0.0001 | |
| AQR Capital | $26,224.00 | 0.05 | 28,818 | -96.52% | -$727,972.16 | <0.0001 | |
| Fidelis Capital Partners Llc | $23,117.00 | 0.05 | 25,403 | New | +$23,117.00 | <0.01 | |
| American International Group | $20,976.00 | 0.04 | 23,050 | -0.85% | -$180.18 | <0.0001 | |
| Mackenzie Financial Corp | $19,270.00 | 0.04 | 21,176 | -60.55% | -$29,576.57 | <0.0001 | |
| Mirae Asset Global Investments Co Ltd | $104,797.00 | 0.04 | 21,214 | New | +$104,797.00 | <0.0001 | |
| Rathbone Brothers | $18,349.00 | 0.04 | 20,164 | 0% | +$0 | <0.0001 | |
| Wells Fargo | $17,678.00 | 0.04 | 19,427 | +5.51% | +$923.62 | <0.0001 | |
| State Board of Administration of Florida | $91,056.00 | 0.03 | 18,545 | +52.62% | +$31,394.56 | <0.0001 |